Generating Evidence of Value
THU 30 SEPTEMBER | 14:00-17:30 GMT
Adaptive pathways promise a "triple win”.
They enable early access for patients to the most promising innovative therapies, address concerns over affordability, cost-effectiveness and outcome uncertainty for payers, whilst meeting companies’ need to make R&D sustainable.
As such they are a critical tool in the market access toolbox, but their opportunities and challenges are not well understood.
Uncertainty remains on how to realise all the potential benefits, when adaptive pathways are superior to traditional market entry routes, and how to overcome real-world evidence generation challenges.
This Masterclass addresses these strategic issues, illuminating when adaptive pathways are optimal for innovative therapies, as well as bringing together multiple perspectives on these iterative pathways.
Participants will benefit from engaging with OHE’s global thought leaders, and from industry insights on successful examples of adaptive pathways applications, which have aligned regulatory and reimbursement evidentiary requirements to enable timely access to breakthrough therapies.
The Masterclass speakers will also reflect on the practical opportunities and potential barriers to the acceptability of real-world evidence, and will present optimal evidence generation plans for different treatment types.
* A reduced rate is available for public sector workers. Please email for special registration instructions.